AstraZeneca Completes Acquisition of Amolyt Pharma, Strengthening Rare Disease Division

AstraZeneca has successfully completed the acquisition of Amolyt Pharma, a medical biotechnology company specializing in the development of innovative drugs for the treatment of rare endocrine diseases. The acquisition strengthens the late-stage pipeline of Alexion, the Rare Diseases business of AstraZeneca, and expands the bone metabolism franchise with the investigational Phase III therapeutic peptide eneboparatide (AZP-3601), designed to address key therapeutic targets in hypoparathyroidism.

Key Takeaways:

• AstraZeneca has acquired all outstanding shares of Amolyt Pharma for a total cash consideration of up to $1.05 billion.
• The acquisition includes an upfront payment of $800 million at closing and the right of Amolyt Pharma shareholders to receive an additional contingent payment of $250 million upon the achievement of certain milestones.
• The acquisition will enable Alexion to enter the rare endocrine diseases market with the investigational Phase III therapeutic peptide eneboparatide (AZP-3601).
• Eneboparatide is designed to regulate serum calcium concentrations, reduce urinary calcium excretion, and prevent progressive decline in renal function and the development of chronic kidney disease.
• Hypoparathyroidism affects approximately 115,000 people in the United States and 107,000 people in the European Union, with approximately 80% of these people being women.
• The clinical manifestations of hypoparathyroidism affect many tissues and organ systems, including the kidneys and bone.
• Eneboparatide has a short plasma half-life, allowing for restoration of bone tissue metabolism to more physiological levels and preservation of bone integrity.

Statistics:

• Total cash consideration for the acquisition: up to $1.05 billion
• Upfront payment: $800 million
• Contingent payment: $250 million
• Number of people affected by hypoparathyroidism in the United States: approximately 115,000
• Number of people affected by hypoparathyroidism in the European Union: approximately 107,000
• Percentage of people with hypoparathyroidism that are women: approximately 80%

Sources:

• AstraZeneca original press release, July 18, 2023
• "Epidemiology and diagnosis of hypoparathyroidism" by Clarke BL, et al., J Clin Endocrinol Metab, 2016
• "An open-label phase 2 study of eneboparatide, a novel PTH receptor 1 agonist, in hypoparathyroidism" by Takacs I, et al., J Endocrinol Metab, 2024
• "Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop" by Khan A, et al., J Bone Miner Res, 2022
• "A Population-based study of the Epidemiology of Chronic Hypoparathyroidism" by Vadiveloo, T, et al., J Bone Miner Res, 2018
• "Influence of gender and women's age on the prevalence of parathyroid failure after total thyroidectomy for multinodular goiter" by Villarroya-Marquina I, et al., Gland Surg, 2020
• "Hypoparathyroidism" by Bilezikian JP, J Clin Endocrinol Metab, 2020
• "Review of Hypoparathyroidism" by Abate EG, et al., Front Endocrinol (Lausanne), 2017
• "Hypoparathyroidism" by Bilezikian JP, J Clin Endocrinol Metab, 2020